{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:08:20Z","timestamp":1782202100207,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["obgyn.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obstetrics and Gynecology Clinics of North America"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ogc.2017.05.005","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T02:31:37Z","timestamp":1501641097000},"page":"421-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fissures, Herpes Simplex Virus, and Drug Reactions"],"prefix":"10.1016","volume":"44","author":[{"given":"Tanja G.","family":"Bohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogc.2017.05.005_bib1","unstructured":"The Australian STI Management Guidelines. Available at: http:\/\/www.sexualhealthalliance.org.au\/ASHA. Accessed April 2016."},{"issue":"12","key":"10.1016\/j.ogc.2017.05.005_bib2","first-page":"949","article-title":"Membranous hypertrophy of the posterior fourchette as a cause of dyspareunia and vulvodynia","volume":"39","author":"Barbero","year":"1994","journal-title":"J\u00a0Reprod Med"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00002018-200730050-00003","article-title":"Drug-related problems in hospitals: a review of the recent literature","volume":"30","author":"Krahenbuhl-Melcher","year":"2007","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00128071-200001050-00003","article-title":"Fixed drug eruptions. Incidence, recognition, and avoidance","volume":"1","author":"Lee","year":"2000","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.ogc.2017.05.005_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0190-9622(87)70220-5","article-title":"Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline","volume":"17","author":"Shelley","year":"1987","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib6","first-page":"81","article-title":"Vulvar fixed drug eruption. A report of 13 cases","volume":"52","author":"Fischer","year":"2007","journal-title":"J\u00a0Reprod Med"},{"issue":"4","key":"10.1016\/j.ogc.2017.05.005_bib7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.12133","article-title":"Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"168","author":"Lipowicz","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ogc.2017.05.005_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archderm.1984.01650400102024","article-title":"Fixed drug eruption. A brief review","volume":"120","author":"Korkij","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ogc.2017.05.005_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-4632.2006.02786.x","article-title":"Fixed drug eruption may be sexually induced","volume":"45","author":"Zawar","year":"2006","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.ogc.2017.05.005_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm.3883","article-title":"The emerging role of resident memory T\u00a0cells in protective immunity and inflammatory disease","volume":"21","author":"Park","year":"2015","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ogc.2017.05.005_bib11","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In\u00a0vivo dynamics of intraepidermal CD8+ Tcells and CD4+ Tcells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ogc.2017.05.005_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11882-009-0011-8","article-title":"Fixed drug eruption: a prototypic disorder mediated by effector memory T\u00a0cells","volume":"9","author":"Mizukawa","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.ogc.2017.05.005_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0190-9622(94)70007-9","article-title":"Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22","volume":"30","author":"Pellicano","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ogc.2017.05.005_bib14","series-title":"Skin pathology","first-page":"42","article-title":"The lichenoid reaction pattern (\u2018interface dermatitis\u2019)","author":"Weedon","year":"2002"},{"issue":"4","key":"10.1016\/j.ogc.2017.05.005_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.ogc.2017.05.005_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)64410-0","article-title":"Direct evidence for interferon-gamma production by effector-memory-type in intraepidermal T\u00a0cells residing at an effector site of immunopathology in fixed drug eruption","volume":"161","author":"Mizukawa","year":"2002","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1529-8019.2009.01260.x","article-title":"Clinical risk management of Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"22","author":"Knowles","year":"2009","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.ogc.2017.05.005_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.ogc.2017.05.005_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib20","doi-asserted-by":"crossref","first-page":"173.e1-13","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ogc.2017.05.005_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","article-title":"Evaluation of SCORTEN on a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study","volume":"32","author":"Sekula","year":"2011","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.ogc.2017.05.005_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/ph4010069","article-title":"Drug induced hypersensitivity and the HLA complex","volume":"4","author":"Alfirevic","year":"2011","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ogc.2017.05.005_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib27","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2011.10.007","article-title":"Prognostic value of histologic features of toxic epidermal necrolysis","volume":"68","author":"Valeyrie-Allanore","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ogc.2017.05.005_bib28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ogc.2017.05.005_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: comparison with case\u2013control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ogc.2017.05.005_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1365-4632.2007.03277.x","article-title":"Practical guidelines for the management of toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"46","author":"Fromowitz","year":"2007","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.ogc.2017.05.005_bib31","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bjps.2014.04.003","article-title":"Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm","volume":"67","author":"Abela","year":"2014","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"issue":"2","key":"10.1016\/j.ogc.2017.05.005_bib32","first-page":"81","article-title":"Prevention of vulvovaginal sequelae in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Kaser","year":"2011","journal-title":"Rev Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00404-009-1008-1","article-title":"Relevance and consequences of erythema multiforme, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in gynecology","volume":"280","author":"Niemeijer","year":"2009","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/BCR.0b013e3181eed441","article-title":"Toxic epidermal necrolysis in pregnancy: case report and review of the literature","volume":"31","author":"Struck","year":"2010","journal-title":"J\u00a0Burn Care Res"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib35","first-page":"322","article-title":"Risk of nevirapine-associated Stevens\u2013Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007\u20132012","volume":"103","author":"Dube","year":"2013","journal-title":"S\u00a0Afr Med J"},{"issue":"4","key":"10.1016\/j.ogc.2017.05.005_bib36","doi-asserted-by":"crossref","first-page":"e93543","DOI":"10.1371\/journal.pone.0093543","article-title":"Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Knight","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ogc.2017.05.005_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cis891","article-title":"Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women","volume":"56","author":"Bernstein","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.ogc.2017.05.005_bib38","first-page":"456","article-title":"Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years\u2014United States, 2005-2008","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.ogc.2017.05.005_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/jit458","article-title":"Seroprevalence of herpes simplex virus types 1 and 2\u2014United States, 1999-2010","volume":"209","author":"Bradley","year":"2014","journal-title":"J\u00a0Infect Dis"},{"issue":"14","key":"10.1016\/j.ogc.2017.05.005_bib40","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ogc.2017.05.005_bib41","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1056\/NEJMcp023065","article-title":"Clinical practice. Genital herpes","volume":"350","author":"Kimberlin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ogc.2017.05.005_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7326\/0003-4819-131-1-199907060-00004","article-title":"Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time","volume":"131","author":"Benedetti","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ogc.2017.05.005_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS"},{"issue":"9605","key":"10.1016\/j.ogc.2017.05.005_bib44","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ogc.2017.05.005_bib45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","article-title":"The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics","volume":"35","author":"Corey","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.ogc.2017.05.005_bib46","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1086\/593214","article-title":"Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2\/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial","volume":"198","author":"Baeten","year":"2008","journal-title":"J\u00a0Infect Dis"}],"container-title":["Obstetrics and Gynecology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854517300803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889854517300803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:27:29Z","timestamp":1535560049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889854517300803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0889854517300803"],"URL":"https:\/\/doi.org\/10.1016\/j.ogc.2017.05.005","relation":{},"ISSN":["0889-8545"],"issn-type":[{"value":"0889-8545","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fissures, Herpes Simplex Virus, and Drug Reactions","name":"articletitle","label":"Article Title"},{"value":"Obstetrics and Gynecology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogc.2017.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}